key: cord-0820342-3qdoyrs0
authors: Supekar, Nitin T.; Shajahan, Asif; Gleinich, Anne S.; Rouhani, Daniel; Heiss, Christian; Azadi, Parastoo
title: SARS-CoV-2 Nucleocapsid protein is decorated with multiple N- and O-glycans
date: 2020-08-27
journal: bioRxiv
DOI: 10.1101/2020.08.26.269043
sha: 0e7383a2062eaeaf2a8c5a6bf3637aaaa058c7f1
doc_id: 820342
cord_uid: 3qdoyrs0

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease (COVID-19) started at the end of 2019 in Wuhan, China has spread rapidly and became a pandemic. Since there is no therapy available that is proven as fully protective against COVID-19, a vaccine to protect against deadly COVID-19 is urgently needed. Nucleocapsid protein (N protein), is one of the most abundant proteins in coronaviruses and is a potential target for both vaccine development and point of care diagnostics. The variable mass of N protein (45 to 60 kDa), suggests the presence of post-translational modifications (PTMs), and it is critical to clearly define these PTMs to gain the structural understanding necessary for further vaccine research. There have been several reports suggesting that the N protein is phosphorylated but lacks glycosylation. Our comprehensive glycomics and glycoproteomics experiments confirm that the N protein is highly O-glycosylated and also contains significant levels of N-glycosylation. We were able to confirm the presence of O-glycans on seven sites with substantial glycan occupancy, in addition to less abundant O-glycans on four sites. We also detected N-glycans on two out of five potential N-glycosylation sites. Moreover, we were able to confirm one phosphorylation site. Recent studies have indicated that the N protein can serve as an important diagnostic marker for coronavirus disease and a major immunogen by priming protective immune responses. Thus, detailed structural characterization of the N protein may provide useful insights for understanding the roles of glycosylation on viral pathogenesis and also in vaccine design and development.

In early December 2019 in Wuhan, China, an outbreak of disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), commonly known as 2019 coronavirus disease (COVID- 19) , spread rapidly and became a worldwide pandemic. 1 According to the World Health Organization (WHO) report, as of August 25, 2020, there have been 23.7 million confirmed cases of COVID 19 globally, including over 814,000 deaths. Along with other medically advanced countries like Italy, Spain, France and Germany, the United States of America (USA) is one of the most affected countries in the world. To date, the USA alone has over 5.7 million confirmed cases and over 176,000 deaths due to COVID-19. 2 Therefore, a vaccine to protect against COVID-19 is urgently needed. Multiple preclinical studies have shown positive results, but despite the continuous efforts by the scientific community towards a vaccine or a specific treatment, no vaccine is currently available in USA or Europe that is proven effective and protective against COVID-19. [3] [4] The coronavirus virion consists of a nucleocapsid that is surrounded by a lipid envelope in which the membrane glycoprotein (M) and small transmembrane protein (E) are embedded.

Protrusions composed of trimeric glycoproteins (Spike protein, S) are anchored in the lipid envelope and extend radially ( Figure 1 ). These Spike proteins give the spherical viral particles an appearance reminiscent of the solar corona, hence the name for this group of viruses. The S protein is one of the most studied proteins in SARS-CoV-2 and has been under evaluation as a vaccine target. 4 The S protein is highly glycosylated and binds to angiotensin converting enzyme 2 (hACE2) for entry into the cells. A number of studies have highlighted the importance of spike protein glycans, which play a critical role in the mechanism of virus attachment to the hACE2 receptor. CD8 + T cells are known to detect and neutralize virus-infected cells by recognizing viral protein-derived peptide epitopes presented by major histocompatibility complex class I (MHC-I) proteins on the cell surface. 5 Recently, however, a study involving SARS-CoV-2 patients identified the majority of immunodominant CD8 + T cell epitopes from virus proteins other than the S protein, and leading to the conclusion that more protein targets need to be included for new and more effective vaccine design. 6 The nucleocapsid (N) protein is one of the most abundant proteins in the coronavirus.

Numerous copies of the N protein interact with RNA molecules during the viral life cycle. The N protein, in conjunction with the membrane (M) protein, also contributes towards genome condensation and packaging. The C-terminal interactions between the N and M proteins result in specific genome encapsidation during the budding process of the viral particle. The N protein has a molecular mass ranging from 45 to 60 kDa -possibly due to PTMs -and is highly basic in nature. 7 After sequence comparison of various strains, it is believed that the majority of N proteins are composed of three highly conserved domains known as Domains 1, 2 and 3. 7-8 Domains 1 and 2 are rich in arginine and lysine, a characteristic feature of several viral RNA-binding proteins.

The carboxy-terminal Domain 3 is short and contains a net negative charge due to multiple acidic residues. 7 Mapping studies of SARS-CoV-2 and other coronaviruses, including the closely related SARS coronavirus (retrospectively named SARS-CoV-1), which was the cause of an epidemic in 2003, have linked the RNA-binding function to a fragment of 55 amino acids located at the N-terminal half that resides in Domain 1, and the dimerization function to its C-terminal half from Domain 3 of the N protein. The linker region (LKR) is located in the middle of the protein sequence, connects the N-and C-terminal domains of the protein and includes a Ser/Arg-rich (S/R-rich) region. 9 Studies have shown that the S/R-rich LKR contains multiple putative sites of phosphorylation that may play a role in regulating N protein function and N-M protein interactions. [10] [11] [12] [13] The N protein interacts with viral genome RNA to form long, flexible, helical ribonucleoprotein (RNP) complexes. One of the structural models of coronaviruses (CoV) proposes that numerous copies of the N protein are present in the form of a helical nucleocapsid as well as in the internal spherical or icosahedral core. 14 The internal core of CoV is composed of N protein, RNA and the C-terminal dimerization domain (CTD) of M protein. 9 The M protein is the main core shell component, and the CTD of M protein binds directly to the N protein through an ionic interaction resulting in specific genome encapsidation in the budding viral particle. This way, the N protein plays an important structural role in the CoV virion through a series of interactions with the genomic RNA, M protein and other N proteins. Along with the structural roles, the N protein is also associated with other processes such as mRNA transcription, replication, and host cell modulation during viral infection. Interestingly, nucleocapsid proteins of MERS-CoV and SARS-CoV-1 were found to antagonize interferons (INFs). [15] [16] [17] Early studies investigating the SARS-CoV-2 N protein show similar results in the suppression of interferon induction. [18] [19] INFs are signaling molecules of the innate immune system of the host and have been identified as a crucial component in the early phase of viral disease. In detail, type I and type III interferons serve as the first important step of antiviral defense mechanisms that induce downstream antiviral processes. 20 Studies found that the antagonistic role of the N protein leads to a modulation of the innate immune response of the host, weakening primary antiviral responses. An initial viral evasion from innate immunity affects the course of the disease tremendously. 3, 21 The N protein can also serve as an important diagnostic marker for coronavirus disease and a major immunogen by priming protective immune responses. The recent mass spectrometry (MS) -based studies of SARS-CoV-2 proteins from gargle solution samples and nasal swab samples of COVID-19 patients detected the presence of N protein peptides, making them a potential diagnostic biomarker for COVID-19. [22] [23] The presence of N protein peptides in the gargle and nasopharyngeal swabs could be used to develop a point of care high throughput test for fast detection of SARS-CoV-2. The authors demonstrated in these studies that SARS-CoV-2 peptidome detection through tandem mass spectrometry can be used as alternative methodologies to PCR and immunodiagnostics. The clinical study on gargle solution showed that peptide 41 RPQGLPNNTASWFTALTQHGK 61 from the N protein which comprises an Nglycosylation site can only be detected on COVID-19 positive cases after the removal of Nglycosylations by PNGase F treatment. 22 Whereas in the latter study, the authors argued that the N protein peptides ADETQALPQR and GFYAQGSR can be detected with intense signal within short retention time on COVID-19 clinical samples. 23 These recent findings on COVID-19 clinical samples show the presence of N protein by the virus on the host and the potential as a diagnostic biomarker at point of care.

A study of SARS-CoV-2 patients noted that 26 of 29 specific T cell epitopes came from proteins other than the S protein. 6 Importantly, out of these 29 immunodominant epitopes, 6 derived from the N protein. This makes the N protein a potential target for a new vaccine design which would comprise more than one antigen to elicit a CD8 + T cell response against SARS-CoV-2. 6 Early studies, including recent review articles about the N protein, suggested that the N protein is a phosphoprotein and does not bear glycans on its backbone. 24 Glycan-detecting software and amino acid sequence analysis have lately indicated the considerable likelihood of the presence of N-and O-glycans. To our knowledge, however, glycan profiling and site-specific information of N-and O-glycans in the N protein have not been described. To discover the PTMs of N protein, we explored several high-resolution MS-based approaches, including glycomics, glycoproteomics, and phosphoproteomics analyses. Our study has revealed new information about the PTMs of N protein: We demonstrate that the SARS-CoV-2 N protein is not only a phosphoprotein but also carries significant amounts of N-and O-glycosylation. MS experiments to determine occupancy and site-specific microheterogeneity, sialic acid linkages, fucosylation and investigation of bisecting GlcNAc of N-linked glycans were also conducted. In our study, we detected mostly high-mannose and complex type glycans, as well as minor percentages of hybrid N-glycans through the glycomics approach. These findings were confirmed in our glycoproteomic investigation: We confirmed presence of N-glycosylation on two of five consensus sequons, which were modified with mostly either high-mannose or complex type N-glycans. Along with N-linked glycosylation, we also observed O-linked glycosylation on the N protein via glycomics and glycoproteomics. Proteomic analysis for O-glycosylation and phosphorylation resulted in the detection of 8 glycopeptides with 11 potential O-glycan sites and one phosphate modification site.

We accomplished detailed structure characterization of the glycans of N protein that was recombinantly expressed in HEK293 cells using full MS and MS n experiments of the released and permethylated glycans. The N protein was initially purified using SDS-PAGE for both N-and O-glycomics experiments (Fig. S1 ). The N-glycans were released from the cut gel band by treatment with PNGase F enzyme. The released N-glycans were extracted from the gel pieces We observed mostly high-mannose type N-glycans (~73%), along with smaller amounts of complex (~22%) and hybrid type (~5%) glycans. Sialylated and non-sialylated glycan structures with multiple fucosylation were observed in lesser abundance (~7%) ( Fig. 3A and Table S1 ). We confirmed the structure of the permethylated N-glycans by ESI-MS n . Interestingly, we also observed terminal GalNAc structures and lack of branching other than biantennary, and these are discussed in the corresponding sections below.

The O-glycans detected on the N protein were Core 1, Core 2, Core 3, and Core 4 types; however, Core 1 and Core 2 types were predominant, comprising 96% of total O-glycans ( Figure   3B and Table S2 ). As shown in, Core 3 and Core 4 structures, which are formed by the activity of the Core 3 GlcNAcT and Core 4 GlcNAcT enzymes, 25 were relatively low ( Figure 3B and Table   S2 ). The structural features such as branching, sialic acid linkage, position of fucose on O-glycans were also confirmed by ESI-MS n .

We evaluated the type of branching on the released N-glycans from N protein by ESI-MSn analysis. Interestingly, we did not observe any evidence for the presence of common tri-or tetraantennary and bisecting GlcNAc structures. Instead, we observed uncommon N-glycans with terminal GalNAc and sialic acid linked GalNAc structures. Such GalNAc-GlcNAc-R (LacdiNAc, LDN) glycan structures are known to play critical role in many biological processes and are considered key determinants that can be recognized by the adaptive and innate immune systems via multiple carbohydrate-binding proteins. 26 Figure   4A ).

We evaluated the presence of core and antennal fucosylation on N-glycan structures and observed that core fucosylations were predominant (Table S1 ). However, we observed monofucosylated structures that presented both antennal and core fucosylation. We observed only 2,3 linked sialic acid on the O-glycans released from N protein ( Figure 4D ).

Since our glycomics analysis confirmed the presence of N-glycans on the N protein, we were interested in determining the site-specific glycan distribution. For this purpose, we used trypsin and elastase proteases both separately and sequentially to produce three glycopeptide (Figures S42-S46) . The ETD experiments suggested that glycosylation is present at site S23 (fragments c8, c9, z9 and c10) ( Figure S42 ). However, we observed that the glycan occupancy at S23 was only about 2% as shown in Figure S113 . HCD and CID MS 2 analysis of glycopeptide 144 DHIGTR 149 confirmed the O-glycosylation at T148 by the presence of glycan oxonium ions, peptide fragments (b and y ions) and glycan neutral losses ( Figures S47-S51) . The overall glycan occupancy at the site T148 was determined with ~81%, out of which mono-and di-sialyl Core 2 type glycans (~70%) were the predominant ones ( Figure   7B , Table S3 ). The Byonic glycopeptide search showed a strong indication for the presence of glycan on the peptide 159 LQLPQGTTLPK 169 . To further evaluate the glycosylation in this peptide, we manually validated full mass, HCD and CID MS 2 spectra that showed presence of oxonium ions, b and y peptide fragments along with peaks for mass of peptide and peptide+HexNAc ( Figure S53 ). This glycopeptide contains two possible O-glycosylation sites, the ETD experiment for the site mapping of T165 or T166 in the peptide 159 LQLPQGTTLPK 169 detected two spectra that showed c and z ions indicating that some of these peptides are O-glycosylated on T165 and others on T166 ( Figures S68 and S69 ). As shown in ETD MS 2 spectra, the diagnostic peaks z5 at m/z 908.57 and c7 at m/z 1120.57 for the presence of glycan at site T165 were observed ( Figure S68) . Similarly, the diagnostic peaks z4 at m/z 807.36 and c8 at m/z 1221.65 for presence of glycans at site T166 ( Figure S69 ) were detected. It was found that the peptide 159 LQLPQGTTLPK 169 is almost fully occupied with glycans and Core 1 type structures were predominant ones by comprising 77% of total glycans at these sites ( Figure 7B ). However, we also detected Core 2 to Core 4 type of glycans including extended Core 2 glycan with fucose and sialic acid on the peptide 159 LQLPQGTTLPK 169 (Figures S52-S69 is glycosylated ( Figure 5D ). At site T391 di-sialylated Core 1 to Core 2 type glycans were predominant over other glycans (Figures 7B and S91-S105, Table S4 ). Interestingly, site S404 was found to contain only mono-and di-sialylated Core 2 type structures as shown in Figures S106-S108. We confirmed the O-glycan structures and glycosylation sites through both Byonic software search, as well as manual analysis. In summary, as shown in Figure 7B the sites T148, T165, T166, T205, S206, T391, and S404 showed the presence of significant levels of Oglycosylation (47%-90%) and the sites S23, T245, T247 and T379 indicated a lower level (1%-9%) of O-glycosylation (Figures S113-S115). We identified Core 1, Core 2, Core 3, and Core 4 type O-glycans at these sites, confirming the glycomics analysis findings ( Figure 3B and Table   S2 ).

N proteins from coronaviruses such as SARS-CoV-1 (Uniprot ID P59595) and MERS-CoV (Uniprot ID K9N4V7, uniprot.org) have been known as phosphoproteins. 33 However, to the best of our knowledge, there are no reports of site-specific phosphorylation for SARS-CoV-2, therefore we included the identification of phosphorylation sites present on SARS-CoV-2 N protein. 13 We Figures 4D and S109) . Interestingly, the peptide with phosphorylation modification also has Core 1 to Core 4 type O-linked glycosylation, including fucosylated glycans, as shown in Figure 7B and Table S4 . Additionally, we identified a longer peptide with phosphorylation on glycopeptide 389 QQTVTLLPAADLDDFSK 405 that contains three potential sites -T391, T393 and S404confirming the glycosylation and phosphorylation. The presence of a phosphate in the peptide was confirmed by CID MS2 experiments using the highresolution precursor mass and neutral losses of phosphate (loss of m/z 79.9663) from the glycopeptide ( Figure S112 ). As shown in the deconvoluted CID MS2 spectrum in Figure S112 , the peak at m/z 2964.30 represents the glycopeptide fragment 389 QQTVTLLPAADLDDFSK 405 bearing the glycan HexNAc2Hex2NeuAc1 and phosphate, and peak at m/z 2884.34 represents the same peptide with glycan HexNAc2Hex2NeuAc1 showing neutral loss of one phosphate group.

The alignment of the N protein sequences of SARS-CoV-1 (ID P59595, 422 amino acids), MERS-CoV (ID K9N4V7, 411 amino acids) and SARS-CoV-2 (ID P0DTC9, 419 amino acids) via UniProt reveals that the N protein from SARS-CoV-1 and SARS-CoV-2 is highly conserved, sharing about 90% similarity. This is in agreement with other studies that used slightly different sequences/alignments. [34] [35] The N protein sequence of MERS-CoV shares only 42% to 44% similarity with the SARS-CoV-1 and SARS-CoV-2 N protein, respectively.

As shown in Figure 2B , 

The coronavirus N protein consists of three distinct but highly conserved domains, including an N-terminal RNA-binding domain (NTD), a C-terminal dimerization domain (CTD), and a central Ser/Arg (SR)-rich linker domain, which displays an intrinsically disordered structure and facilitates molecular movements to aid interactions. The NTD is reportedly responsible for RNA binding, CTD for oligomerization, and the SR-rich linker is generally known to be primarily involved in phosphorylation events. [36] [37] [38] However, no site specific glycosylation nor phosphorylation was reported in any of these domains in the current literature on SARS-CoV-2. Our LC-MS/MS studies have shown that the N protein contains N-and O-glycosylation, in addition to phosphorylation.

The coronavirus N protein-NTD associates with the 3′ end of the viral RNA genome through electrostatic interactions. 39 In the NTD, we identified one N-glycosylation site (N47) and three O-glycosylation sites (T148, T165 and T166), which possibly play a role in regulating the RNAbinding activity. In the CTD, we observed minor O-glycosylation at sites T245 and T247 and Nglycosylation at site N269. Considering the role of CTD in oligomerization and self-association, future studies on the role of the glycosylation is of vital importance. 40 The detailed structural analysis of the PTMs on the N protein of the newly emerged SARS-CoV-2 could be a key aspect in the development of therapeutic agents that specifically and efficiently block the coronavirus replication, transcription, and viral assembly. 36 To our knowledge, the CoV N protein is the only phosphorylated structural protein on the virus, and this phosphorylation has been proposed to play a role in regulating its functions. [41] [42] [43] Evidence of significant conformational changes in the N protein structure due to phosphorylation has been reported. 44 Importantly, N protein from SARS-CoV-1 have been shown to elicit a well-defined immunological response, which underscores the importance of the N protein as a potent target for a vaccine against COVID-19 infection. 45 A recent study aimed to investigate effect of early SARS-CoV-2-specific humoral immune responses on disease outcome found that deceased patient had stronger antibody responses towards N protein while survivors had much more stronger antibody response to S protein highlighting the importance of N protein in disease outcome. 46 Therefore, understanding the N protein glycosylation patterns described in this study may ultimately help in new vaccine design to prevent SARS-CoV-2 infection.

Sequencing-grade modified trypsin and elastase were purchased from Promega (Madison, WI).

Peptide-N-Glycosidase F (PNGase F) was purchased from New England Biolabs (Ipswich, MA).

All other reagents were purchased from Sigma Aldrich unless indicated otherwise. Data analysis was performed using Byonic 2.3 software and manually using Xcalibur 4. 

The N protein was purified using SDS-PAGE prior to glycomic analysis ( Figure S1 ) Original glycoform assignments were made based on full-mass molecular weight. Additional structural details were determined by ESI-MS n and analysis with GlycoWorkbench 1.1 software.

The purified N protein (20 µg 

The glycoprotein digests were analyzed on an Orbitrap Fusion Tribrid mass spectrometer equipped with a nanospray ion source and connected to a Dionex binary solvent system (Thermo 

The raw data files and search results can be accessed from glycopost repositoryhttps://glycopost.glycosmos.org/preview/11350896155f46ae870bcc3; Pin: 2697.

Financial support from the US National Institutes of Health (S10OD018530) is gratefully acknowledged. 

The authors certify that they have do not have any competing interests.

Supplemental material: SDS-PAGE-purification (S1), Glycomics and Glycoproteomics workflow of N protein (S2), N-and O-glycan MALDI/ESI-MS data (S3-S5), Annotated glycopeptide MS/MS spectra (S6 -S112), O-Glycoform quantification for S23, T245, T247 and T379 -(S113-S115) and are incorporated as a separate supplemental material file. Supplemental Tables 1-4 are also included as separate files for relative quantification via glycomics and glycoproteomics.

A Novel Coronavirus from Patients with Pneumonia in China

T cell responses to viral infections -opportunities for Peptide vaccination

Patients Form Memory CD8+ T Cells that Recognize a Small Set of Shared Immunodominant Epitopes in SARS-CoV-2. medRxiv 2020

The Molecular Biology of Coronaviruses

Sequence comparison of the N genes of five strains of the coronavirus mouse hepatitis virus suggests a three domain structure for the nucleocapsid protein

The SARS coronavirus nucleocapsid protein--forms and functions

Characterization of protein-protein interactions between the nucleocapsid protein and membrane protein of the SARS coronavirus

Phosphorylation of the arginine/serine dipeptide-rich motif of the severe acute respiratory syndrome coronavirus nucleocapsid protein modulates its multimerization, translation inhibitory activity and cellular localization

The severe acute respiratory syndrome coronavirus nucleocapsid protein is phosphorylated and localizes in the cytoplasm by 14-3-3-mediated translocation

Glycogen synthase kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus nucleocapsid protein and viral replication

The transmissible gastroenteritis coronavirus contains a spherical core shell consisting of M and N proteins

Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists

The nucleocapsid proteins of mouse hepatitis virus and severe acute respiratory syndrome coronavirus share the same IFN-β antagonizing mechanism: attenuation of PACTmediated RIG-I/ MDA5 activation

Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Suppresses Type I and Type III Interferon Induction by Targeting RIG-I Signaling

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19

Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples

Proteotyping SARS-CoV-2 Virus from Nasopharyngeal Swabs: A Proof-of-Concept Focused on a 3 Min Mass Spectrometry Window

Biochemical characterization of SARS-CoV-2 nucleocapsid protein

Essentials of Glycobiology

In Vivo Targeting Function of N-Linked Oligosaccharides

Mannose receptor-mediated regulation of serum glycoprotein homeostasis

Novel Poly-GalNAcβ1-4GlcNAc (LacdiNAc) and Fucosylated Poly-LacdiNAc N-Glycans from Mammalian Cells Expressing β1,4-N-Acetylgalactosaminyltransferase and α1,3-Fucosyltransferase

Glycan microarray profiling of parasite infection sera identifies the LDNF glycan as a potential antigen for serodiagnosis of trichinellosis

The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x

Glycomic and glycoproteomic analysis of glycoproteins-a tutorial

Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

Biochemical characterization of SARS-CoV-2 nucleocapsid protein

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Modular organization of SARS coronavirus nucleocapsid protein

Phosphorylation of the porcine reproductive and respiratory syndrome virus nucleocapsid protein

Coronavirus N protein N-terminal domain (NTD) specifically binds the transcriptional regulatory sequence (TRS) and melts TRS-cTRS RNA duplexes

The dimer interface of the SARS coronavirus nucleocapsid protein adapts a porcine respiratory and reproductive syndrome virus-like structure

Mass spectroscopic characterization of the coronavirus infectious bronchitis virus nucleoprotein and elucidation of the role of phosphorylation in RNA binding by using surface plasmon resonance

Phosphorylation and subcellular localization of transmissible gastroenteritis virus nucleocapsid protein in infected cells

Identification of phosphorylation sites in the nucleocapsid protein (N protein) of SARS-coronavirus

Synthesis and subcellular localization of the murine coronavirus nucleocapsid protein

High-resolution structure of HLA-A*1101 in complex with SARS nucleocapsid peptide

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Relative percentage of N-glycans at sites N47 shows complex type glycans and N269 shows majority of high mannose type of glycan with Man5 structure is the most abundant; B. Relative percentage of O-glycans at sites T148, T165, T166, T205, S206, T391, and S404. Phosphorylation is detected on T393. These sites showed major glycan occupancy ranging from 47%-99%. Minor O-glycosylated site distribution is shown in SI. Otherminor glycoforms with less than 2 % abundances.